Evidence map›Paper›PMID 26719343›Full record

ArticleThe Journal of biological chemistry2016

Inhibition of RPE65 Retinol Isomerase Activity by Inhibitors of Lipid Metabolism.

Abdulkerim Eroglu, Susan Gentleman, Eugenia Poliakov, T Michael Redmond

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 0 citations in OpenAlex.

  1. Advances and therapeutic opportunities in visual cycle modulation.Progress in retinal and eye research · 2025
    Review
  2. Retinal pigment epithelium 65 kDa protein (RPE65): An update.Progress in retinal and eye research · 2022
    Review
  3. Article
  4. Article
  5. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration.Biochimica et biophysica acta. Molecular basis of disease · 2018
    Article
  6. Article
  7. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Abdulkerim ErogluFrom the Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Susan GentlemanFrom the Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
Eugenia PoliakovFrom the Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
T Michael RedmondFrom the Laboratory of Retinal Cell & Molecular Biology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 redmondd@helix.nih.gov.
National Eye Institute · US

Funding

Molecular Biology Of Outer Retina-specific ProteinsZIAEY000260 · NEI · NATIONAL EYE INSTITUTE · PI REDMOND, T. MICHAEL · 2009 to 2025
$26.0M
Intramural NIH HHS
6 · The paper itself

Abstract

RPE65 is the isomerase catalyzing conversion of all-trans-retinyl ester (atRE) into 11-cis-retinol in the retinal visual cycle. Crystal structures of RPE65 and site-directed mutagenesis reveal aspects of its catalytic mechanism, especially retinyl moiety isomerization, but other aspects remain to be determined. To investigate potential interactions between RPE65 and lipid metabolism enzymes, HEK293-F cells were transfected with expression vectors for visual cycle proteins and co-transfected with either fatty acyl:CoA ligases (ACSLs) 1, 3, or 6 or the SLC27A family fatty acyl-CoA synthase FATP2/SLCA27A2 to test their effect on isomerase activity. These experiments showed that RPE65 activity was reduced by co-expression of ACSLs or FATP2. Surprisingly, however, in attempting to relieve the ACSL-mediated inhibition, we discovered that triacsin C, an inhibitor of ACSLs, also potently inhibited RPE65 isomerase activity in cellulo. We found triacsin C to be a competitive inhibitor of RPE65 (IC50 = 500 nm). We confirmed that triacsin C competes directly with atRE by incubating membranes prepared from chicken RPE65-transfected cells with liposomes containing 0-1 μM atRE. Other inhibitors of ACSLs had modest inhibitory effects compared with triascin C. In conclusion, we have identified an inhibitor of ACSLs as a potent inhibitor of RPE65 that competes with the atRE substrate of RPE65 for binding. Triacsin C, with an alkenyl chain resembling but not identical to either acyl or retinyl chains, may compete with binding of the acyl moiety of atRE via the alkenyl moiety. Its inhibitory effect, however, may reside in its nitrosohydrazone/triazene moiety.

Indexed as

Amino Acid SequenceAnimalsBinding SitesChickenscis-trans-IsomerasesCoenzyme A LigasesEnzyme InhibitorsHEK293 CellsHumansMolecular Sequence DataProtein BindingRetinoid IsomerohydrolaseTriazenescis-trans-IsomerasesCoenzyme A LigasesEnzyme InhibitorsRetinoid Isomerohydrolasetriacsin CTriazenesenzyme inhibitorfatty acyl:CoA ligaseliposomeretinal metabolismretinoidRPE65triacsin Cvisionvisual cycle

Identifiers

PMID26719343
PMCPMC4777834
OpenAlexW754217580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.